Vivimed Labs Limited enters Corporate Insolvency Resolution Process
Vivimed Labs Limited notified the National Stock Exchange (NSE) of the commencement of Corporate Insolvency Resolution Process on 17 June 2026, per the NSE archives filing 'Updates_to_CIRP.pdf'. The CIRP is the statutory insolvency resolution mechanism under the Insolvency and Bankruptcy Code, 2016, typically initiated following an admission order by the National Company Law Tribunal (NCLT). During CIRP, an Insolvency Professional assumes management of the corporate debtor and creditors file claims toward a resolution plan or liquidation outcome within a 180-day statutory window (extendable by 90 days).
Why it mattersCIRP entry by a listed pharma entity triggers mandatory exchange disclosure, trading restrictions pending resolution, and creditor claim procedures under IBC-key gating event for restructuring or liquidation path and stakeholder recovery timeline.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives · official
- IBBI orders · official
- NCLT orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026